PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:PDLI
- CUSIP: 69329Y10
- Web: www.pdl.com
Capitalization:- Market Cap: $429.89 million
- Outstanding Shares: 154,080,000
Average Prices:- 50 Day Moving Avg: $2.45
- 200 Day Moving Avg: $2.29
- 52 Week Range: $1.93 - $3.77
P/E:- Trailing P/E Ratio: 6.41
- Foreward P/E Ratio: 12.13
- P/E Growth: 0.33
Sales & Book Value:- Annual Revenue: $143.37 million
- Price / Sales: 3.00
- Book Value: $5.31 per share
- Price / Book: 0.53
Profitability:- EBIDTA: $69.37 million
- Net Margins: 23.03%
- Return on Equity: 9.07%
- Return on Assets: 5.64%
Debt:- Debt-to-Equity Ratio: 0.14%
- Current Ratio: 1.94%
- Quick Ratio: 1.90%
Misc:- Average Volume: 1.64 million shs.
- Beta: 0.58
- Short Ratio: 9.19
Frequently Asked Questions for PDL BioPharma (NASDAQ:PDLI)
What is PDL BioPharma's stock symbol?
PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."
How will PDL BioPharma's stock buyback program work?
PDL BioPharma declared that its Board of Directors has authorized a share repurchase program on Saturday, April 8th 2017, which allows the company to repurchase $30,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 8.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.
How were PDL BioPharma's earnings last quarter?
PDL BioPharma, Inc. (NASDAQ:PDLI) released its quarterly earnings results on Thursday, August, 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.17. The business had revenue of $143.80 million for the quarter, compared to analyst estimates of $56.30 million. PDL BioPharma had a net margin of 23.03% and a return on equity of 9.07%. The firm's revenue for the quarter was up 584.8% on a year-over-year basis. During the same period last year, the company earned $0.09 EPS. View PDL BioPharma's Earnings History.
Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?
2 brokers have issued 12 month price objectives for PDL BioPharma's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate PDL BioPharma's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for PDL BioPharma.
What are analysts saying about PDL BioPharma stock?
Here are some recent quotes from research analysts about PDL BioPharma stock:
- 1. According to Zacks Investment Research, "PDL BioPharma reported better than expected earnings in the first quarter of 2017 whereas revenue significantly decreased year over year. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, whereby it is making equity investments in product-focused companies. However, the company’s dependence on revenues from royalties is not a risk-free strategy. Moreover, the company’s top line declined materially after it stopped receiving payments from certain Queen et al. patent license. The decrease in royalties from PDL's Queen et al. patents is due to the expiration of the patent license agreement with Genentech. PDL BioPharma’s shares have underperformed the Medical-Biomedical/Genetics industry in the past one year." (5/15/2017)
- 2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)
Who are some of PDL BioPharma's key competitors?
Some companies that are related to PDL BioPharma include Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Spectrum Pharmaceuticals (SPPI), CRISPR THERAPTC (CRSP), TG Therapeutics (TGTX), Cellectis S.A. (CLLS), Enanta Pharmaceuticals (ENTA), Intellia Therapeutics (NTLA), Mesoblast Limited (MESO), ImmunoGen (IMGN), ANI Pharmaceuticals (ANIP), Inovio Pharmaceuticals (INO), Kala Pharmctls (KALA), WAVE Life Sciences (WVE), Cara Therapeutics (CARA), AC Immune SA (ACIU), Celyad SA (CYAD) and Agenus (AGEN).
Who are PDL BioPharma's key executives?
PDL BioPharma's management team includes the folowing people:
- John Peter McLaughlin, President, Chief Executive Officer, Director
- Peter S. Garcia, Chief Financial Officer, Vice President
- Steffen Pietzke CPA, Chief Accounting Officer, Vice President - Finance
- Christopher Lewis Stone J.D., Vice President, General Counsel, Secretary
- Danny Hart, Vice President - Business Development
- Harold E. Selick Ph.D., Lead Independent Director
- Paul R. Edick, Independent Director
- David W. Gryska, Independent Director
- Jody S. Lindell, Independent Director
- Samuel R. Saks M.D., Independent Director
Who owns PDL BioPharma stock?
PDL BioPharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.99%), Renaissance Technologies LLC (6.65%), Dimensional Fund Advisors LP (4.61%), State Street Corp (3.27%), Acadian Asset Management LLC (3.00%) and Schwab Charles Investment Management Inc. (1.79%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.
Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?
PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., GSA Capital Partners LLP, Canada Pension Plan Investment Board, JPMorgan Chase & Co., Numeric Investors LLC, FMR LLC and Aperio Group LLC. View Insider Buying and Selling for PDL BioPharma.
Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?
PDL BioPharma's stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Kestrel Investment Management Corp, Brandes Investment Partners LP, Northern Trust Corp, State Street Corp, Schwab Charles Investment Management Inc., Sterling Capital Management LLC and Parametric Portfolio Associates LLC. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.
How do I buy PDL BioPharma stock?
Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PDL BioPharma's stock price today?
One share of PDL BioPharma stock can currently be purchased for approximately $2.79.
MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $4.00 (43.37% upside) |
Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/10/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $4.00 | Medium |  |
| 5/3/2017 | Cowen and Company | Reiterated Rating | Hold | | High | |
| 2/23/2016 | Royal Bank Of Canada | Lower Price Target | Sector Perform | $5.00 -> $4.00 | N/A | |
(Data available from 8/16/2015 forward)
Earnings History for PDL BioPharma (NASDAQ:PDLI)Earnings History by Quarter for PDL BioPharma (NASDAQ PDLI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | $0.09 | $0.26 | $56.30 million | $143.80 million | View | Listen | |
| 5/3/2017 | Q1 2017 | $0.05 | $0.08 | | $45.44 million | View | Listen | |
| 11/3/2016 | Q316 | $0.08 | $0.08 | $50.69 million | $53.60 million | View | N/A | |
| 8/4/2016 | Q216 | $0.08 | $0.09 | $33.46 million | $21.00 million | View | N/A | |
| 5/4/2016 | Q116 | $0.50 | $0.52 | $142.05 million | $103.10 million | View | N/A | |
| 2/22/2016 | Q415 | $0.54 | $0.61 | $149.20 million | $178.10 million | View | Listen | |
| 11/4/2015 | Q315 | $0.61 | $0.42 | $164.80 million | $124.60 million | View | N/A | |
| 8/5/2015 | Q215 | $0.52 | $0.47 | $137.75 million | $138.10 million | View | N/A | |
| 5/6/2015 | Q115 | $0.52 | $0.50 | $140.80 million | $149.71 million | View | N/A | |
| 2/23/2015 | Q414 | $0.57 | $0.32 | $158.15 million | $117.10 million | View | Listen | |
| 11/10/2014 | Q314 | $0.56 | $0.61 | $165.10 million | $164.60 million | View | N/A | |
| 8/18/2014 | Q214 | $0.46 | $0.52 | $134.07 million | $162.80 million | View | Listen | |
| 5/12/2014 | Q114 | $0.45 | $0.44 | $130.93 million | $139.70 million | View | N/A | |
| 3/3/2014 | Q413 | $0.43 | $0.39 | $115.22 million | $110.10 million | View | N/A | |
| 11/6/2013 | Q313 | $0.37 | $0.36 | $97.09 million | $97.30 million | View | N/A | |
| 8/8/2013 | Q2 2013 | $0.54 | $0.62 | $138.20 million | $143.60 million | View | N/A | |
| 5/9/2013 | Q1 2013 | $0.35 | $0.36 | $91.69 million | $91.80 million | View | N/A | |
| 3/1/2013 | Q4 2012 | $0.31 | $0.34 | $86.08 million | $86.10 million | View | N/A | |
| 11/5/2012 | Q312 | $0.33 | $0.32 | $85.03 million | $85.20 million | View | N/A | |
| 8/2/2012 | | $0.44 | $0.52 | | | View | N/A | |
| 5/3/2012 | | $0.27 | $0.29 | | | View | N/A | |
| 2/23/2012 | | $0.28 | $0.24 | | | View | N/A | |
| 11/9/2011 | | $0.27 | $0.28 | | | View | N/A | |
| 7/27/2011 | | $0.39 | $0.39 | | | View | N/A | |
| 4/27/2011 | | $0.24 | $0.25 | | | View | N/A | |
| 2/28/2011 | | $0.21 | $0.20 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $0.23 EPS
Dividend History by Quarter for PDL BioPharma (NASDAQ PDLI)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/4/2016 | quarterly | $0.05 | 6.25% | 6/2/2016 | 6/6/2016 | 6/13/2016 |
| 2/1/2016 | quarterly | $0.05 | 7.27% | 3/2/2016 | 3/4/2016 | 3/11/2016 |
| 2/2/2015 | quarterly | $0.15 | 8.22% | 6/1/2016 | 6/5/2016 | 6/12/2016 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 6/3/2015 | 6/5/2015 | 6/12/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 3/3/2015 | 3/5/2015 | 3/12/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 12/2/2015 | 12/4/2015 | 12/11/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 9/2/2015 | 9/4/2015 | 9/11/2015 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 9/3/2014 | 9/5/2014 | 9/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 3/3/2014 | 3/5/2014 | 3/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 12/3/2014 | 12/5/2014 | 12/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 6/3/2014 | 6/5/2014 | 6/12/2014 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 12/3/2013 | 12/5/2013 | 12/12/2013 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 6/3/2013 | 6/5/2013 | 6/12/2013 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 9/3/2013 | 9/5/2013 | 9/12/2013 |
| 1/30/2013 | quarterly | $0.15 | 8.72% | 3/1/2013 | 3/5/2013 | 3/12/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for PDL BioPharma (NASDAQ:PDLI)Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 87.72%
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/24/2017 | Peter S Garcia | VP | Buy | 25,000 | $1.98 | $49,500.00 | |
| 8/9/2016 | Peter S Garcia | VP | Buy | 10,000 | $3.00 | $30,000.00 | |
| 12/15/2015 | Peter S. Garcia | CFO | Buy | 5,000 | $3.64 | $18,200.00 | |
| 12/14/2015 | Peter S. Garcia | CFO | Buy | 10,000 | $3.42 | $34,200.00 | |
| 12/7/2015 | Steffen Pietzke | CAO | Buy | 20,590 | $3.64 | $74,947.60 | |
| 8/14/2015 | Peter S Garcia | CFO | Buy | 20,000 | $5.83 | $116,600.00 | |
| 11/26/2014 | Harold E Selick | Director | Buy | 6,000 | $8.08 | $48,480.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for PDL BioPharma (NASDAQ:PDLI)
Latest Headlines for PDL BioPharma (NASDAQ:PDLI)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to PDL BioPharma, Inc. : August 14, 2017
finance.yahoo.com - August 15 at 6:09 AM |
 | PDL BioPharma, Inc. (PDLI) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - August 13 at 12:44 AM |
| PDL BioPharma, Inc. (PDLI) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - August 6 at 10:02 AM |
| PDL BioPharma, Inc. (PDLI) Releases Earnings Results, Beats Expectations By $0.17 EPS
www.americanbankingnews.com - August 5 at 6:44 PM |
| PDL BioPharma, Inc. (PDLI) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 5 at 1:28 PM |
 | Here's Why PDL BioPharma Inc. Is Soaring Today - Motley Fool
www.fool.com - August 5 at 6:03 AM |
| Here's Why PDL BioPharma Inc. Is Soaring Today
finance.yahoo.com - August 5 at 6:03 AM |
| BidaskClub Lowers PDL BioPharma, Inc. (PDLI) to Sell
www.americanbankingnews.com - August 4 at 9:20 PM |
| Here's Why PDL BioPharma Inc. Is Soaring Today
www.fool.com - August 4 at 2:03 PM |
 | EARNINGS SUMMARY: Details of PDL BioPharma Inc. Q2 Earnings Report
www.rttnews.com - August 4 at 6:53 AM |
| PDL BioPharma Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 6:52 AM |
| ETFs with exposure to PDL BioPharma, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 6:52 AM |
| Edited Transcript of PDLI earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 6:52 AM |
| PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : August 4, 2017
finance.yahoo.com - August 4 at 6:52 AM |
| PDL BioPharma to Announce Second Quarter 2017 Financial Results on August 3, 2017
finance.yahoo.com - August 1 at 1:47 AM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 31, 2017
finance.yahoo.com - August 1 at 1:46 AM |
| Zacks: Analysts Anticipate PDL BioPharma, Inc. (NASDAQ:PDLI) Will Post Earnings of $0.09 Per Share
www.americanbankingnews.com - July 30 at 8:20 PM |
| ETFs with exposure to PDL BioPharma, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 7:47 PM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 21, 2017
finance.yahoo.com - July 22 at 7:29 AM |
| PDL BioPharma, Inc. (NASDAQ:PDLI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - July 19 at 8:00 PM |
| PDL BioPharma, Inc. (PDLI) Short Interest Up 13.0% in June
www.americanbankingnews.com - July 15 at 7:16 AM |
| ETFs with exposure to PDL BioPharma, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 7:19 AM |
| PDL BioPharma, Inc. (NASDAQ:PDLI) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 11 at 12:40 PM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 10, 2017
finance.yahoo.com - July 11 at 6:31 AM |
| $0.09 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - July 6 at 4:24 PM |
| ETFs with exposure to PDL BioPharma, Inc. : July 3, 2017
finance.yahoo.com - July 4 at 5:51 AM |
| Short Interest in PDL BioPharma, Inc. (PDLI) Grows By 16.1%
www.americanbankingnews.com - June 28 at 7:12 AM |
| ETFs with exposure to PDL BioPharma, Inc. : June 20, 2017
finance.yahoo.com - June 21 at 1:32 AM |
| PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 19 at 7:53 PM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : June 19, 2017
finance.yahoo.com - June 19 at 10:31 AM |
| Zacks: Analysts Anticipate PDL BioPharma, Inc. (PDLI) to Announce $0.09 Earnings Per Share
www.americanbankingnews.com - June 12 at 4:48 PM |
 | PDL BioPharma (PDLI) Presents At Jefferies 2017 Global Healthcare Conference
seekingalpha.com - June 7 at 7:02 PM |
 | Noden Pharma Notified of ANDA Filing for Tekturna® - PR Newswire - PR Newswire (press release)
www.prnewswire.com - June 6 at 8:21 AM |
| Noden Pharma Notified of ANDA Filing for Tekturna®
finance.yahoo.com - June 5 at 8:23 AM |
| ValuEngine Downgrades PDL BioPharma Inc (PDLI) to Hold
www.americanbankingnews.com - June 3 at 5:40 PM |
| PDL BioPharma to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 1 at 7:57 PM |
| PDL BioPharma: Now Is The Time To Buy - Seeking Alpha
seekingalpha.com - May 19 at 11:57 AM |
| Brokerages Expect PDL BioPharma Inc (PDLI) to Announce $0.04 EPS
www.americanbankingnews.com - May 16 at 10:46 AM |
| PDL BioPharma Inc (PDLI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:22 PM |
| LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR
finance.yahoo.com - May 11 at 8:32 AM |
| PDL BioPharma Inc (PDLI) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 6 at 1:00 AM |
 | LENSAR Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam Tomographers (PDLI)
www.streetinsider.com - May 5 at 7:26 PM |
| LENSAR® Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam® Tomographers
finance.yahoo.com - May 5 at 7:26 PM |
| PDL BioPharma Inc (PDLI) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 2:30 PM |
| Edited Transcript of PDLI earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 8:06 AM |
| PDL BioPharma's (PDLI) "Hold" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - May 4 at 12:06 AM |
| Cowen and Company Reiterates "Hold" Rating for PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - May 4 at 12:00 AM |
| EARNINGS SUMMARY: Details of PDL BioPharma Inc. Q1 Earnings Report
www.rttnews.com - May 3 at 7:53 PM |
| Investor Network: PDL BioPharma, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 7:53 PM |
| PDL BioPharma Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 7:53 PM |
PDL BioPharma (PDLI) Chart for Wednesday, August, 16, 2017
